The rollercoaster history of using physiological and pharmacological properties of incretin hormones to develop diabetes medications with a convincing benefit-risk relationship

Incretin-based glucose-lowering medications (glucagon-like peptide-1 receptor agonists, GLP-1 RAs, and inhibitors of dipeptidyl peptidase-4, DPP-4 I) are now established drug classes, widely used because of their ability to substantially reduce high plasma glucose concentrations and levels of glycated hemoglobin without themselves causing hypoglycemic episodes, doing so without prompting body weight gain (DPP-4-I) or even with a chance to meaningfully reduce adipose tissue mass (GLP-1 RA) [1, 2].
Source: Metabolism - Clinical and Experimental - Category: Biomedical Science Authors: Source Type: research